Wealthbridge Acquisition Limited — 2019 Form 10-K
Reporting period and business context. This is Wealthbridge Acquisition Limited’s annual report for the year ended December 31, 2019, filed March 20, 2020; it does not provide standalone fourth-quarter results. Although the request identifies Scienjoy, the filing is by Wealthbridge, a British Virgin Islands blank-check company. Its activity was seeking a business combination, and it had no operating revenue. In October 2019, Wealthbridge agreed to acquire Scienjoy; the transaction had not closed as of the filing.
Financial results and liquidity
| Metric | 2019 | Comparison / context |
|---|---|---|
| Revenue | None | Wealthbridge had not begun operating activities that generate revenue. |
| Net income | $151,393 | Compared with a $60,837 net loss from inception on May 2 through December 31, 2018. The periods are not comparable full years. |
| Interest and unrealized gain | $1,085,110 interest income; $3,028 unrealized gain | Earned on trust-account securities. |
| Operating costs | $936,745 | Compared with $60,837 in the 2018 inception period. |
| Operating cash flow | $(715,669) | Cash used in operations. |
| Trust-account investments | $58,588,138 | Includes interest and unrealized gains; primarily U.S. Treasury bills. Funds were generally restricted to a business combination or liquidation. |
| Cash outside trust | $11,610 | Available for working capital at year-end. |
| Liabilities | $2,700,050 | Includes $2,012,500 deferred underwriting fees and $465,641 related-party promissory note. |
| Temporary equity | $50,900,529 | 4,995,517 ordinary shares classified as subject to possible redemption. |
The filing reports basic and diluted loss per ordinary share of $0.35 for 2019, despite positive net income of $151,393. It explains that income attributable to redeemable shares is excluded from the company’s earnings available to ordinary shares; the adjusted net loss used in the per-share calculation was $793,981. No operating margin is meaningful because the company had no revenue.
Material developments, outlook and risks
- Proposed Scienjoy acquisition: Under the share exchange agreement, Wealthbridge would acquire all Scienjoy equity for approximately 16.4 million Wealthbridge shares, including 1.64 million held in escrow for seller indemnification. Additional shares may be earned against specified Scienjoy pretax-income targets for 2019–2021 or post-closing share-price targets. Closing remained subject to transaction conditions and shareholder action.
- Extension financing: In January 2020, Scienjoy provided $575,000 under a non-interest-bearing note deposited into the trust to extend the combination deadline from February 8 to May 8, 2020. The note is payable at closing or, at the lender’s option, convertible into private units.
- Deadline and liquidation: If no business combination is completed within the applicable period, Wealthbridge must redeem public shares and liquidate, subject to creditor claims and applicable law. Warrants and rights could expire worthless, and public shareholders may receive less than $10 per share if claims reduce trust assets.
- COVID-19: Management warned that pandemic-related travel restrictions, market disruption, or unavailability of target personnel and service providers could delay or prevent the acquisition or another business combination.
- Funding and dilution: The company had limited cash outside the trust and may need additional financing, particularly if shareholders redeem a significant number of shares. The transaction also entails potential dilution from seller earnouts, warrants, rights, underwriter options, advisory fees, and convertible related-party financing.
- Other obligations and conflicts: Wealthbridge owed a $2.0125 million deferred underwriting fee payable upon a business combination, paid its sponsor $10,000 monthly for administrative services, and had related-party arrangements. Management and directors disclosed competing affiliations and potential conflicts in allocating opportunities.
- Controls and contingencies: Management concluded disclosure controls were effective at December 31, 2019. The report did not include management’s internal-control assessment or auditor attestation, citing the SEC transition period for newly public companies. No material litigation was reported.
Management provided no operating guidance or financial outlook for Scienjoy’s business in this filing. Wealthbridge said it expected continued costs while pursuing an acquisition and could not assure that the transaction would close. The financial statements received an unqualified audit opinion.
Investor verification priorities
- Check subsequent filings for whether the Scienjoy transaction closed, its final terms, and any shareholder redemptions or financing.
- Verify Scienjoy’s actual 2019 results against the agreement’s pretax-income earnout threshold and review the associated share issuance conditions.
- Confirm the applicable business-combination deadline, any further extensions, and repayment or conversion of the $575,000 note.
- Review trust-account balances, creditor claims, deferred underwriting and advisory fees, and cash available outside the trust.
- Assess potential dilution from earnouts, warrants, rights, options, and related-party loans, and review the disclosed conflicts of interest.